Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
Reprod Biol Endocrinol ; 14(1): 53, 2016 Sep 02.
Article in English | MEDLINE | ID: mdl-27589950

ABSTRACT

BACKGROUND: In Spanish public hospital Reproduction Units it is very problematic to perform programmed intrauterine insemination (IUI) on weekends, if indicated. Small previous pilot studies suggest that using a GnRH antagonist to avoid an LH weekend surge would allow to perform IUI on the following Monday, not impairing the expected pregnancy rate. METHODS: Between 1st January 2007 and 31st December 2015, 4.782 intrauterine inseminations were performed at Valladolid University Clinic, Spain, corresponding to 1.650 women. Of them, 911, corresponding to 695 women, should ideally have been performed during the weekend. If it happened that a member of the Reproduction Unit was on duty during that particular weekend, the standard protocol was not interrupted, and the IUI performed as planned (control group, 685 IUIs). If the former was not the case, the weekend gap was bridged by administering 0.25 mg GnRH antagonist (GnRHa). Ovulation was induced by means of 250 ug recombinant HCG (rHCG) 36 h prior to IUI on the following Monday (study group, 226 IUIs). RESULTS: There were no differences in the clinical pregnancy rate (13.7 cc vs. 16.2 %, p = 0.371) or in the ongoing pregnancy rate between groups (11.9 % vs. 14.9 %, p = 0.271). The multiple pregnancy rate was also comparable in both groups (14.7 % vs. 18.5 %, p = 0.77). CONCLUSIONS: Women with a planned IUI which cannot be performed at the ideal date can be offered postponement for two days with the support of GnRHa treatment, with results that are not inferior to those expected applying the regular protocol.


Subject(s)
Gonadotropin-Releasing Hormone/antagonists & inhibitors , Hormone Antagonists/pharmacology , Hospitals, Public/methods , Insemination, Artificial/methods , Pregnancy Rate , Adult , Cohort Studies , Female , Humans , Pilot Projects , Pregnancy , Pregnancy Rate/trends , Retrospective Studies , Spain/epidemiology , Time Factors
2.
Clín. investig. ginecol. obstet. (Ed. impr.) ; 27(3): 103-106, mar. 2000. ilus
Article in Es | IBECS | ID: ibc-20925

ABSTRACT

El cáncer de mama es el tumor maligno más frecuente y la primera causa de muerte por cáncer en las mujeres. La mayoría de las neoplasias malignas son adenocarcinomas, y desde el punto de vista arquitectural la forma más frecuente es el carcinoma ductal infiltrante, seguida del lobulillar infiltrante. Ambos tipos histológicos pueden diseminarse por vía hematógena a cualquier órgano, siendo el hueso, pulmón e hígado los más afectados con más frecuencia. Otras estructuras como el peritoneo, meninges o aparato genital se afectan más raramente, y en estos casos el tipo lobulillar infiltrante es el causante de las metástasis la mayor parte de las veces. Presentamos el caso clínico de una paciente de 44 años sometida en nuestro servicio a tratamiento quirúrgico mediante mastectomía radical modificada por tumoración mamaria, cuyo resultado anatomopatológico fue carcinoma ductal con áreas de lobulillar infiltrante. En el curso del seguimiento clínico, y a los 47 meses de la intervención, se objetiva un incremento de los marcadores tumorales, así como una masa bilateral ovárica cuyo origen metastásico es comprobado tras la exéresis quirúrgica. Este caso nos sirve para hacer hincapié en la condición de enfermedad sistémica que caracteriza al cáncer de mama, y en la posibilidad de metástasis en órganos diferentes de los habituales, incluido el aparato genital, en especial si el tumor primario tiene componente lobulillar (AU)


Subject(s)
Female , Middle Aged , Humans , Biopsy/methods , Mammography/methods , Carcinoma/complications , Carcinoma/diagnosis , Tomography, Emission-Computed/methods , Paclitaxel/therapeutic use , Neoplasm Metastasis/physiopathology , Neoplasm Metastasis/diagnosis , Breast Neoplasms/complications , Breast Neoplasms/diagnosis , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/drug therapy , Doxorubicin/therapeutic use , Pelvis/pathology , Pelvis , Biomarkers, Tumor/analysis , Biomarkers, Tumor
SELECTION OF CITATIONS
SEARCH DETAIL
...